AstraZeneca PLC (LSE/STO/NYSE: AZN) announced on 16 November 2026 that the US Food and Drug Administration has approved Imfinzi (durvalumab) in combination with enfortumab vedotin as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment after radical cystectomy, for adult patients with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. The approval, which secured Priority Review, is based on data from the Phase III VOLGA trial showing a 49% reduction in risk of disease recurrence and a 42% reduction in risk of death versus the comparator arm. This marks AstraZeneca's third bladder cancer indication for Imfinzi in two years, reinforcing the drug's role as an immunotherapy backbone across both muscle-invasive and non-muscle-invasive disease.

Key Points

  • AstraZeneca PLC (AZN) — global biopharmaceutical company headquartered in Cambridge, UK
  • FDA approved Imfinzi plus enfortumab vedotin as the first perioperative immunotherapy regimen for cisplatin-ineligible muscle-invasive bladder cancer patients
  • VOLGA Phase III trial showed 49% reduction in event-free survival risk (HR 0.51; p<0.0001) and 42% reduction in overall survival risk (HR 0.58; p=0.0027); approximately 16,000 patients will be treated for MIBC in the US in 2026
  • Investors may be watching regulatory reviews currently under way in the EU, Japan and several other countries based on the same VOLGA data

VOLGA Phase III Trial Data Supporting the FDA's Priority Review Decision

The approval was grounded in a planned interim analysis from the VOLGA trial, in which 695 patients across 182 centres in 25 countries were randomised across three arms. Patients in the approved regimen arm received three cycles of Imfinzi and enfortumab vedotin before radical cystectomy, followed by nine cycles of Imfinzi adjuvant monotherapy. Estimated median event-free survival was not yet reached for the Imfinzi combination versus 12.1 months for the comparator arm. An estimated 64% of patients in the combination arm remained alive and event-free at two years, compared with 45% in the comparator arm. Results were presented at the 2026 ESMO Congress and simultaneously published in The New England Journal of Medicine.

Overall Survival Benefit and Safety Profile Recorded in MIBC Cisplatin-Ineligible Patients

On the key secondary endpoint of overall survival, an estimated 78% of patients treated with the Imfinzi combination were alive at two years compared with 69% in the comparator arm, with estimated median overall survival not yet reached in either arm. Grade 3 and 4 adverse events due to any cause occurred in 64% of patients in the combination arm and 44% in the comparator arm. The announcement states that the safety and tolerability profile was consistent with the known profiles of the individual medicines, with no new safety signals identified. Patient-reported quality of life was maintained after surgery in patients receiving the Imfinzi combination.

Imfinzi's Expanding Bladder Cancer Footprint and Unmet Medical Need in MIBC

Around 16,000 patients will be treated for muscle-invasive bladder cancer in the United States in 2026, with as many as 50% ineligible for cisplatin-based chemotherapy owing to impaired renal function or comorbidities. Historically, those patients faced radical cystectomy alone, with high recurrence rates and poor prognosis. Imfinzi is already approved in over 50 countries for cisplatin-eligible MIBC patients based on the NIAGARA trial, and in combination with BCG therapy for high-risk non-muscle-invasive bladder cancer in the US and Japan based on the POTOMAC trial, making this the drug's third bladder cancer approval in two years.

Pending International Reviews and Broader Imfinzi Pipeline Context

Regulatory applications based on VOLGA data are currently under review in the European Union, Japan and several other countries, representing the next significant milestones investors may monitor. Beyond bladder cancer, Imfinzi holds approvals across multiple oncology indications including non-small cell lung cancer, small cell lung cancer, biliary tract cancer, hepatocellular carcinoma, and endometrial cancer, with an estimated 600,000 patients treated since its first approval in May 2017. A specific risk for AstraZeneca is that international regulators may reach different benefit-risk conclusions from the VOLGA data than the FDA, which could limit the addressable patient population outside the United States.